Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00277498 · ClinicalTrials.gov registry record · Phase 3
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
A Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 528
- Enrollment target
- 20
- Study locations
NCT00277498 is a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 528 participants, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00277498, a Phase 3 study of Ocular Hypertension and Open Angle Glaucoma, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 528 participants
- Enrollment target
- 20
- Study locations
Study Summary
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Conditions Studied
Interventions
- DRUG Timolol
- DRUG Xalacom
- DRUG Xalatan
Study Locations (20)
California
- Pfizer Investigational Site - Artesia
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Newport Beach
- Pfizer Investigational Site - Sacramento
- Pfizer Investigational Site - San Francisco
Florida
- Pfizer Investigational Site - Gainesville
- Pfizer Investigational Site - Lecanto
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Panama City
Illinois
- Pfizer Investigational Site - Bourbonnais
- Pfizer Investigational Site - Calumet City
- Pfizer Investigational Site - Chicago
- Pfizer Investigational Site - Chicago
Indiana
- Pfizer Investigational Site - Evansville
- Pfizer Investigational Site - Madison
- Pfizer Investigational Site - New Albany
Alabama
- Pfizer Investigational Site - Birmingham
Arizona
- Pfizer Investigational Site - Flagstaff
Colorado
- Pfizer Investigational Site - Colorado Springs
Idaho
- Pfizer Investigational Site - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00277498
The ClinicalTrials.gov registry entry for NCT00277498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 268-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (97% higher). The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Timolol is the first listed.
NCT00277498 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00277498 about?
NCT00277498 is a clinical study titled "A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma". To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
What is the current status of trial NCT00277498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 528 participants. The study started on 2005-12. Estimated completion is 2007-06.
What conditions does trial NCT00277498 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT00277498?
The interventions under investigation include: Timolol (DRUG), Xalacom (DRUG), Xalatan (DRUG).
Who is sponsoring clinical trial NCT00277498?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00277498 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
ACTIVE NOT RECRUITING · Phase 3
-
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.